Pharma Focus Asia

Vaxxas Opens World-Class Manufacturing Facility

Monday, June 19, 2023

Vaxxas has announced the opening of its first manufacturing facility in Brisbane, Queensland.

The facility covering an area of 5,500 square metres will support the scale-up of operations for producing HD-MAP vaccines, which will be used in late-stage clinical trials and as the first commercial products.

The new facility aims to increase its manufacturing capacity significantly, leading to the creation of new local jobs that require specialised skills. The expanded capacity will also facilitate the progress of late-stage clinical trials, ultimately allowing to bring the first commercial vaccine products to the market.

The site will significantly increase the manufacturing capacity, creating new local, skilled jobs, while enabling to progress through late-stage clinical trials that will bring the first commercial vaccine products to the market.

One of the key advantages of this new facility is that it enables research and development teams to work closely with manufacturing teams. Additionally, the facility's design and production processes serve as a blueprint for scalable manufacturing, which can be replicated by Vaxxas both domestically and internationally as demand for its platform technology grows.

Cytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024